동반진단 시장 : 용도별, 기술별, 사용자별, 제품별, 국가별로 살펴보는 진단의 미래 - 132개사 전략적 분석, 경영진 및 컨설턴트용 가이드 포함(2026-2030년) - 제5판

Market Overview:

Companion diagnostics (CDx) are in vitro diagnostic tests that provide essential information to determine the safe and effective use of a specific therapeutic drug or biologic. These tests identify biomarkers that predict whether a patient is likely to respond positively to a targeted therapy, or whether the therapy may cause adverse effects. Regulatory agencies such as the U.S. FDA define companion diagnostics as medical devices essential for guiding treatment decisions and improving patient outcomes.

The CDx market has become a critical component of precision medicine, particularly in oncology, where molecular profiling allows clinicians to match therapies with patients most likely to benefit. Over the past decade, pharmaceutical companies have increasingly co-developed therapeutics alongside diagnostic assays, resulting in a strong interdependence between drug development pipelines and molecular testing technologies.

Market Size and Growth Outlook:

The global companion diagnostics market is experiencing strong growth, driven by advances in genomics, biomarker discovery, and targeted drug development.

Market Size 2025: USD $8.34B Market Size 2030: USD $15.4B CAGR: 13.1%

Key Market Drivers

Expansion of Targeted Therapies:

The primary driver of the CDx market is the rapid expansion of targeted therapies, particularly in oncology. Many modern drugs require biomarker confirmation prior to prescription, ensuring appropriate patient selection and improving clinical outcomes. Kinase inhibitors, immunotherapies, antibody-drug conjugates (ADCs), and other targeted treatments increasingly rely on companion diagnostic testing as part of regulatory approval pathways.

As pharmaceutical pipelines continue to shift toward precision therapies, the number of drug-diagnostic co-development programs has increased significantly. This trend strengthens partnerships between pharmaceutical companies and diagnostic developers, creating long-term commercial relationships and barriers to entry for competitors.

Advances in Molecular Testing Technologies:

Technological advances have significantly improved the performance and accessibility of companion diagnostics. Key technologies include:

• Next-generation sequencing (NGS)
• Polymerase chain reaction (PCR)
• Immunohistochemistry (IHC)
• Fluorescence in situ hybridization (FISH)
• Liquid biopsy platforms

NGS-based tests are particularly important because they allow simultaneous analysis of multiple biomarkers, enabling comprehensive genomic profiling that can support multiple therapeutic decisions from a single sample.

Growth in Immuno-Oncology Applications:

Oncology remains the dominant clinical application segment for companion diagnostics, accounting for the majority of global CDx revenues. The increasing understanding of tumor genomics has led to rapid expansion in biomarker-driven treatment approaches across lung cancer, breast cancer, colorectal cancer, melanoma, and hematologic malignancies.

The oncology CDx segment alone is expected to exceed USD 8 billion by 2030, reflecting strong demand for molecular profiling in clinical oncology practice.

Regulatory Support and Co-development Models

Regulatory agencies increasingly encourage the co-development of drugs and diagnostics to improve safety and therapeutic efficacy. The FDA has approved multiple expanded indications for major CDx platforms such as FoundationOne CDx and Oncomine Dx Target Test, illustrating ongoing growth in biomarker-guided drug labeling.

Co-development models provide economic benefits for pharmaceutical manufacturers by improving clinical trial success rates and reducing the likelihood of ineffective treatments reaching the market.

Market Segmentation

The companion diagnostics market can be segmented by application, technology, user, product and geography.

By Technology:

NGS represents one of the fastest-growing segments due to its ability to detect multiple genetic alterations simultaneously. PCR-based assays remain widely used due to cost efficiency and established clinical workflows. Immunohistochemistry continues to play an important role in protein biomarker detection.

By Therapeutic Area:

Oncology dominates the market, but other therapeutic areas are emerging, including:

• Neurology
• Infectious diseases
• Cardiovascular disease

As biomarker discovery expands, CDx applications are expected to broaden beyond cancer into chronic disease management.

By End User:

• Key end users include:
• Clinical Laboratories
• Pharmaceutical companies
• Contract research organizations (CROs)
• In Vitro Diagnostic companies

Pharmaceutical companies account for a significant share of demand due to their involvement in clinical trials and drug commercialization strategies.

Geographic Trends:

North America currently leads the global market due to advanced healthcare infrastructure, strong regulatory frameworks, and high adoption of precision medicine technologies. Asia-Pacific is expected to exhibit the fastest growth due to expanding healthcare investment and increasing access to genomic testing.

Competitive Landscape

The CDx market is characterized by partnerships between diagnostics companies and pharmaceutical manufacturers. Leading participants include Roche, Thermo Fisher Scientific, Qiagen, Abbott, Agilent Technologies, and Illumina. Many firms focus on developing platform technologies capable of supporting multiple companion diagnostic indications across therapeutic classes.

Strategic collaborations remain a key competitive factor, as diagnostic developers seek alignment with pharmaceutical pipelines. Long-term agreements for co-development and commercialization are common, often involving milestone payments and revenue sharing structures.

Future Outlook

The companion diagnostics market is expected to expand significantly as precision medicine becomes standard clinical practice. Increasing adoption of genomic sequencing, advances in artificial intelligence for biomarker discovery, and broader integration of real-world data are expected to enhance diagnostic accuracy and clinical utility.

Liquid biopsy technologies represent a particularly important emerging opportunity, as they allow non-invasive detection of biomarkers using blood samples rather than tissue biopsies. This approach may enable more frequent monitoring of treatment response and disease progression.

Overall, companion diagnostics are transitioning from a specialized niche into a foundational component of modern healthcare. As personalized therapies become more prevalent, the CDx market is expected to remain one of the fastest-growing segments within the in vitro diagnostics industry.

Table of Contents

1 Market Guides

• 1.1 Strategic Situation Analysis
  • 1.1.1 Strategic Importance within Precision Medicine
  • 1.1.2 Regulatory Complexity and Co-development Risk
  • 1.1.3 Reimbursement and Economic Value Challenges
  • 1.1.4 Technological Disruption and Platform Competition
  • 1.1.5 Partnership Dependencies and Industry Structure
  • 1.1.6 Market Access and Geographic Disparities
  • 1.1.7 Competitive Landscape and Strategic Positioning
  • 1.1.8 Outlook and Strategic Implications
• 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
• 1.3 Guide for Management Consultants and Investment Advisors
• 1.4 Impact of Artificial Intelligence

2 Introduction and Market Definition

• 2.1 What are Companion Diagnostics?
• 2.2 The Personalized Medicine Revolution
• 2.3 Market Definition
  • 2.3.1 Revenue Market Size.
• 2.4 Methodology
  • 2.4.1 Methodology
  • 2.4.2 Sources
  • 2.4.3 Authors
• 2.5 Perspective: Healthcare and the IVD Industry
  • 2.5.1 Global Healthcare Spending
  • 2.5.2 Spending on Diagnostics
  • 2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview

• 3.1 Players in a Dynamic Market
  • 3.1.1 Academic Research Lab
  • 3.1.2 Diagnostic Test Developer
  • 3.1.3 Instrumentation Supplier
  • 3.1.4 Chemical/Reagent Supplier
  • 3.1.5 Pathology Supplier
  • 3.1.6 Independent Clinical Laboratory
  • 3.1.7 Public National/regional Laboratory
  • 3.1.8 Hospital Laboratory
  • 3.1.9 Physicians Office Lab (POLS)
  • 3.1.10 Audit Body
  • 3.1.11 Certification Body
• 3.2 Personalized Medicine and Companion Diagnostics
  • 3.2.1 Basics
  • 3.2.2 Method
  • 3.2.3 Disease risk assessment
  • 3.2.4 Applications
  • 3.2.5 Diagnosis and intervention
    • 3.2.5.1 Companion Diagnostics
  • 3.2.6 Drug development and usage
  • 3.2.7 Respiratory proteomics
  • 3.2.8 Cancer genomics
  • 3.2.9 Population screening
  • 3.2.10 Challenges
  • 3.2.11 Regulatory oversight
  • 3.2.12 Intellectual property rights
  • 3.2.13 Reimbursement policies
  • 3.2.14 Patient privacy and confidentiality
• 3.3 Chromosomes, Genes and Epigenetics
  • 3.3.1 Chromosomes
  • 3.3.2 Genes
  • 3.3.3 Epigenetics
• 3.4 Cancer Genes
  • 3.4.1 Germline vs Somatic
  • 3.4.2 Changing Clinical Role
• 3.5 Structure of Industry Plays a Part
  • 3.5.1 New Pharmaceutical Funding Market
  • 3.5.2 Economies of Scale
    • 3.5.2.1 Hospital vs. Central Lab
  • 3.5.3 Physician Office Labs
  • 3.5.4 Physicians and POCT

4 Market Trends

• 4.1 Factors Driving Growth
  • 4.1.1 Level of Care.
  • 4.1.2 Immuno-oncology.
  • 4.1.3 Liability.
  • 4.1.4 The Aging World
• 4.2 Factors Limiting Growth
  • 4.2.1 State of knowledge.
  • 4.2.2 Genetic Blizzard.
  • 4.2.3 Protocol Resistance.
  • 4.2.4 Regulation and coverage.
• 4.3 Instrumentation, Automation and Diagnostic Trends
  • 4.3.1 Traditional Automation and Centralization
  • 4.3.2 The New Automation, Decentralization and Point Of Care
  • 4.3.3 Instruments Key to Market Share
  • 4.3.4 Bioinformatics Plays a Role
  • 4.3.5 PCR Takes Command
  • 4.3.6 Next Generation Sequencing Fuels a Revolution
  • 4.3.7 NGS Impact on Pricing
  • 4.3.8 Whole Genome Sequencing, A Brave New World
  • 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
  • 4.3.10 Shifting Role of Diagnostics

5 Companion Diagnostics Recent Developments

• 5.1 Recent Developments - Importance and How to Use This Section
  • 5.1.1 Importance of These Developments
  • 5.1.2 How to Use This Section
• 5.2 Strategic collaboration between Leica Biosystems and CellCarta
• 5.3 Allogene Therapeutics Expands Partnership with Foresight Diagnostics
• 5.4 Guardant Health's Shield Screening Test Now Accessible Quest Diagnostics
• 5.5 The Future of Companion Diagnostics: Multi-Omics
• 5.6 Illumina announces new pharma development partnerships
• 5.7 Roche receives CE IVDR approval for HER2 (4B5) CDx
• 5.8 QIAGEN and Incyte Announce Precision Medicine Collaboration
• 5.9 Roche granted FDA Breakthrough Designation for first AI CDx
• 5.10 Agilent Technologies Expands Certification for PD-L1 CDx
• 5.11 Foundation Medicine, Sumitomo Pharma to Develop CDx
• 5.12 Tempus Launches xT CDx
• 5.13 Caris Life Sciences Expands CDx Through Deal With Lumea
• 5.14 FDA Approves Illumina Cancer Genomic Profiling Assay as CDx
• 5.15 Foundation Medicine, Repare to Partner on CDx for Lunresertib
• 5.16 Burning Rock, Bayer to Develop NGS Companion Diagnostic
• 5.17 PathAI, Roche to Develop AI-Enabled Companion Diagnostics
• 5.18 ARUP and Medicover Expand Companion Diagnostic in EU
• 5.19 Thermo Fisher Signs Companion Diagnostic Agreement
• 5.20 Agilent CDx Assay IVDR Certified
• 5.21 ARUP Laboratories Gets Approval for Gene Therapy CDx
• 5.22 Guardant Health Gets Medicare Coverage for Liquid Biopsy Test
• 5.23 Amoy Dx PLC Panel Gets Approval in Japan as CDx
• 5.24 UnitedHealthcare Expands Precision Oncology Dx Coverage
• 5.25 JaxBio to Create Array-Based Cancer Tests

6 Key Players

• 6.1 10x Genomics, Inc.
  • 6.1.1 Role in the CDx ecosystem
  • 6.1.2 Core CDx-related activities
  • 6.1.3 Partnering posture
  • 6.1.4 Differentiators
  • 6.1.5 Commercial situation
  • 6.1.6 Likely next moves
  • 6.1.7 Risks/constraints
• 6.2 Abbott Laboratories
  • 6.2.1 Role in the CDx ecosystem
  • 6.2.2 Core CDx-related activities
  • 6.2.3 Partnering posture
  • 6.2.4 Differentiators
  • 6.2.5 Commercial situation
  • 6.2.6 Likely next moves
  • 6.2.7 Risks/constraints
• 6.3 AccuraGen Inc.
  • 6.3.1 Role in the CDx ecosystem
  • 6.3.2 Core CDx-related activities
  • 6.3.3 Partnering posture
  • 6.3.4 Differentiators
  • 6.3.5 Commercial situation
  • 6.3.6 Likely next moves
  • 6.3.7 Risks/constraints
• 6.4 Acuamark Diagnostics
  • 6.4.1 Role in the CDx ecosystem
  • 6.4.2 Core activities and relevance to CDx
  • 6.4.3 Partnering posture
  • 6.4.4 Differentiators
  • 6.4.5 Commercial situation
  • 6.4.6 Strategy & likely next moves
  • 6.4.7 Risks/constraints
• 6.5 Adaptive Biotechnologies
  • 6.5.1 Role in the CDx ecosystem
  • 6.5.2 Core CDx activities
  • 6.5.3 Partnering posture
  • 6.5.4 Differentiators
  • 6.5.5 Commercial situation
  • 6.5.6 Strategy & likely next moves
  • 6.5.7 Risks/constraints
• 6.6 Admera Health, LLC
  • 6.6.1 Role in the CDx ecosystem
  • 6.6.2 Core CDx-related activities
  • 6.6.3 Partnering posture
  • 6.6.4 Differentiators
  • 6.6.5 Commercial situation
  • 6.6.6 Likely next moves
  • 6.6.7 Risks/constraints
• 6.7 Aethlon Medical
  • 6.7.1 Role in the CDx ecosystem
  • 6.7.2 Core CDx-related activities
  • 6.7.3 Partnering posture
  • 6.7.4 Differentiators
  • 6.7.5 Commercial situation
  • 6.7.6 Likely next moves
  • 6.7.7 Risks/constraints
• 6.8 Agilent
  • 6.8.1 Role in the CDx ecosystem
  • 6.8.2 Core CDx-related activities
  • 6.8.3 Partnering posture
  • 6.8.4 Differentiators
  • 6.8.5 Commercial situation
  • 6.8.6 Likely next moves
  • 6.8.7 Risks/constraints
• 6.9 Amoy Diagnostics Co., Ltd. (AmoyDx)
  • 6.9.1 Role in the CDx ecosystem
  • 6.9.2 Core CDx-related activities
  • 6.9.3 Partnering posture
  • 6.9.4 Differentiators
  • 6.9.5 Commercial situation
  • 6.9.6 Likely next moves
  • 6.9.7 Risks/constraints
• 6.10 Anchor Dx
  • 6.10.1 Role in the CDx ecosystem
  • 6.10.2 Core CDx-related activities
  • 6.10.3 Partnering posture
  • 6.10.4 Differentiators
  • 6.10.5 Commercial situation
  • 6.10.6 Likely next moves
  • 6.10.7 Risks/constraints
• 6.11 ANGLE plc
  • 6.11.1 Role in the CDx ecosystem
  • 6.11.2 Core CDx-related activities
  • 6.11.3 Partnering posture
  • 6.11.4 Differentiators
  • 6.11.5 Commercial situation
  • 6.11.6 Likely next moves
  • 6.11.7 Risks/constraints
• 6.12 Applied DNA Sciences
  • 6.12.1 Role in the CDx ecosystem
  • 6.12.2 Core CDx-related activities
  • 6.12.3 Partnering posture
  • 6.12.4 Differentiators
  • 6.12.5 Commercial situation
  • 6.12.6 Likely next moves
  • 6.12.7 Risks/constraints
• 6.13 ARUP Laboratories
  • 6.13.1 Role in the CDx ecosystem
  • 6.13.2 Core CDx-related activities
  • 6.13.3 Partnering posture
  • 6.13.4 Differentiators
  • 6.13.5 Commercial situation
  • 6.13.6 Likely next moves
  • 6.13.7 Risks/constraints
• 6.14 AVIVA Systems Biology
  • 6.14.1 Role in the CDx ecosystem
  • 6.14.2 Core CDx-related activities
  • 6.14.3 Partnering posture
  • 6.14.4 Differentiators
  • 6.14.5 Commercial situation
  • 6.14.6 Likely next moves
  • 6.14.7 Risks/constraints
• 6.15 Baylor Miraca Genetics Laboratories
  • 6.15.1 Role in the CDx ecosystem
  • 6.15.2 Core CDx-related activities
  • 6.15.3 Partnering posture
  • 6.15.4 Differentiators
  • 6.15.5 Commercial situation
  • 6.15.6 Likely next moves
  • 6.15.7 Risks/constraints
• 6.16 Beckman Coulter Diagnostics (Danaher)
  • 6.16.1 Role in the CDx ecosystem
  • 6.16.2 Core CDx-related activities
  • 6.16.3 Partnering posture
  • 6.16.4 Differentiators
  • 6.16.5 Commercial situation
  • 6.16.6 Likely next moves
  • 6.16.7 Risks/constraints
• 6.17 Becton, Dickinson and Company (BD)
  • 6.17.1 Role in the CDx ecosystem
  • 6.17.2 Core CDx-related activities
  • 6.17.3 Partnering posture
  • 6.17.4 Differentiators
  • 6.17.5 Commercial situation
  • 6.17.6 Likely next moves
  • 6.17.7 Risks/constraints
• 6.18 Berkeley Lights
  • 6.18.1 Role in the CDx ecosystem
  • 6.18.2 Core CDx-related activities
  • 6.18.3 Partnering posture
  • 6.18.4 Differentiators
  • 6.18.5 Commercial situation
  • 6.18.6 Likely next moves
  • 6.18.7 Risks/constraints
• 6.19 BGI Genomics Co. Ltd
  • 6.19.1 Role in the CDx ecosystem
  • 6.19.2 Core CDx-related activities
  • 6.19.3 Partnering posture
  • 6.19.4 Differentiators
  • 6.19.5 Commercial situation
  • 6.19.6 Likely next moves
  • 6.19.7 Risks/constraints
• 6.20 BillionToOne
  • 6.20.1 Role in the CDx ecosystem
  • 6.20.2 Core CDx-related activities
  • 6.20.3 Partnering posture
  • 6.20.4 Differentiators
  • 6.20.5 Commercial situation
  • 6.20.6 Likely next moves
  • 6.20.7 Risks/constraints
• 6.21 Bioarray Genetics
  • 6.21.1 Role in the CDx ecosystem
  • 6.21.2 Core CDx-related activities
  • 6.21.3 Partnering posture
  • 6.21.4 Differentiators
  • 6.21.5 Commercial situation
  • 6.21.6 Likely next moves
  • 6.21.7 Risks/constraints
• 6.22 Biocartis
  • 6.22.1 Role in the CDx ecosystem
  • 6.22.2 Core CDx-related activities
  • 6.22.3 Partnering posture
  • 6.22.4 Differentiators
  • 6.22.5 Commercial situation
  • 6.22.6 Likely next moves
  • 6.22.7 Risks/constraints
• 6.23 Biocept, Inc.
  • 6.23.1 Role in the CDx ecosystem
  • 6.23.2 Core CDx-related activities (historical)
  • 6.23.3 Partnering posture
  • 6.23.4 Differentiators
  • 6.23.5 Likely next moves
  • 6.23.6 Risks/constraints
• 6.24 Biodesix Inc.
  • 6.24.1 Role in the CDx ecosystem
  • 6.24.2 Core CDx-related activities
  • 6.24.3 Partnering posture
  • 6.24.4 Differentiators
  • 6.24.5 Commercial situation
  • 6.24.6 Likely next moves
  • 6.24.7 Risks/constraints
• 6.25 BioFluidica
  • 6.25.1 Role in the CDx ecosystem
  • 6.25.2 Core CDx-related activities
  • 6.25.3 Partnering posture
  • 6.25.4 Differentiators
  • 6.25.5 Commercial situation
  • 6.25.6 Likely next moves
  • 6.25.7 Risks/constraints
• 6.26 BioGenex
  • 6.26.1 Role in the CDx ecosystem
  • 6.26.2 Core CDx-related activities
  • 6.26.3 Partnering posture
  • 6.26.4 Differentiators
  • 6.26.5 Commercial situation
  • 6.26.6 Likely next moves
  • 6.26.7 Risks/constraints
• 6.27 BioIVT
  • 6.27.1 Role in the CDx ecosystem
  • 6.27.2 Core CDx-related activities
  • 6.27.3 Partnering posture
  • 6.27.4 Differentiators
  • 6.27.5 Commercial situation
  • 6.27.6 Likely next moves
  • 6.27.7 Risks/constraints
• 6.28 Biolidics Ltd
  • 6.28.1 Role in the CDx ecosystem
  • 6.28.2 Core CDx-related activities
  • 6.28.3 Partnering posture
  • 6.28.4 Differentiators
  • 6.28.5 Commercial situation
  • 6.28.6 Likely next moves
  • 6.28.7 Risks/constraints
• 6.29 bioMerieux Diagnostics
  • 6.29.1 Role in the CDx ecosystem
  • 6.29.2 Core CDx-related activities
  • 6.29.3 Partnering posture
  • 6.29.4 Differentiators
  • 6.29.5 Commercial situation
  • 6.29.6 Likely next moves
  • 6.29.7 Risks/constraints
• 6.30 Bioneer Corporation
  • 6.30.1 Role in the CDx ecosystem
  • 6.30.2 Core CDx-related activities
  • 6.30.3 Partnering posture
  • 6.30.4 Differentiators
  • 6.30.5 Commercial situation
  • 6.30.6 Likely next moves
  • 6.30.7 Risks/constraints
• 6.31 Bio-Rad Laboratories, Inc
  • 6.31.1 Role in the CDx ecosystem
  • 6.31.2 Core CDx-related activities
  • 6.31.3 Partnering posture
  • 6.31.4 Differentiators
  • 6.31.5 Commercial situation
  • 6.31.6 Likely next moves
  • 6.31.7 Risks/constraints
• 6.32 Bio-Reference Laboratories (BioReference Health)
  • 6.32.1 Role in the CDx ecosystem
  • 6.32.2 Core CDx-related activities
  • 6.32.3 Partnering posture
  • 6.32.4 Differentiators
  • 6.32.5 Commercial situation
  • 6.32.6 Likely next moves
  • 6.32.7 Risks/constraints
• 6.33 Bio-Techne
  • 6.33.1 Role in the CDx ecosystem
  • 6.33.2 Core CDx-related activities
  • 6.33.3 Partnering posture
  • 6.33.4 Differentiators
  • 6.33.5 Commercial situation
  • 6.33.6 Likely next moves
  • 6.33.7 Risks/constraints
• 6.34 BioView
  • 6.34.1 Role in the CDx ecosystem
  • 6.34.2 Core CDx-related activities
  • 6.34.3 Partnering posture
  • 6.34.4 Differentiators
  • 6.34.5 Commercial situation
  • 6.34.6 Likely next moves
  • 6.34.7 Risks/constraints
• 6.35 Bristol-Myers Squibb
  • 6.35.1 Role in the CDx ecosystem
  • 6.35.2 Core CDx-related activities
  • 6.35.3 Partnering posture
  • 6.35.4 Differentiators
  • 6.35.5 Commercial situation
  • 6.35.6 Likely next moves
  • 6.35.7 Risks/constraints
• 6.36 Burning Rock (Burning Rock Biotech)
  • 6.36.1 Role in the CDx ecosystem
  • 6.36.2 Core CDx-related activities
  • 6.36.3 Partnering posture
  • 6.36.4 Differentiators
  • 6.36.5 Commercial situation
  • 6.36.6 Likely next moves
  • 6.36.7 Risks/constraints
• 6.37 C2i Genomics
  • 6.37.1 Role in the CDx ecosystem
  • 6.37.2 Core CDx-related activities
  • 6.37.3 Partnering posture
  • 6.37.4 Differentiators
  • 6.37.5 Commercial situation
  • 6.37.6 Likely next moves
  • 6.37.7 Risks/constraints
• 6.38 Cardiff Oncology
  • 6.38.1 Role in the CDx ecosystem
  • 6.38.2 Core CDx-related activities
  • 6.38.3 Partnering posture
  • 6.38.4 Differentiators
  • 6.38.5 Commercial situation
  • 6.38.6 Likely next moves
  • 6.38.7 Risks/constraints
• 6.39 Caris Molecular Diagnostics (Caris Life Sciences)
  • 6.39.1 Role in the CDx ecosystem
  • 6.39.2 Core CDx-related activities
  • 6.39.3 Partnering posture
  • 6.39.4 Differentiators
  • 6.39.5 Commercial situation
  • 6.39.6 Likely next moves
  • 6.39.7 Risks/constraints
• 6.40 Castle Biosciences, Inc.
  • 6.40.1 Role in the CDx ecosystem
  • 6.40.2 Core CDx-related activities
  • 6.40.3 Partnering posture
  • 6.40.4 Differentiators
  • 6.40.5 Commercial situation
  • 6.40.6 Likely next moves
  • 6.40.7 Risks/constraints
• 6.41 CellCarta
  • 6.41.1 Role in the CDx ecosystem
  • 6.41.2 Core CDx-related activities
  • 6.41.3 Partnering posture
  • 6.41.4 Differentiators
  • 6.41.5 Commercial situation
  • 6.41.6 Likely next moves
  • 6.41.7 Risks/constraints
• 6.42 CellMax Life
  • 6.42.1 Role in the CDx ecosystem
  • 6.42.2 Core CDx-related activities
  • 6.42.3 Partnering posture
  • 6.42.4 Differentiators
  • 6.42.5 Commercial situation
  • 6.42.6 Likely next moves
  • 6.42.7 Risks/constraints
• 6.43 Cepheid (Danaher)
  • 6.43.1 Role in the CDx ecosystem
  • 6.43.2 Core CDx-related activities
  • 6.43.3 Partnering posture
  • 6.43.4 Differentiators
  • 6.43.5 Commercial situation
  • 6.43.6 Likely next moves
  • 6.43.7 Risks/constraints
• 6.44 Charles River Laboratories
  • 6.44.1 Role in the CDx ecosystem
  • 6.44.2 Core CDx-related activities
  • 6.44.3 Partnering posture
  • 6.44.4 Differentiators
  • 6.44.5 Commercial situation
  • 6.44.6 Likely next moves
  • 6.44.7 Risks/constraints
• 6.45 Circulogene
  • 6.45.1 Role in the CDx ecosystem
  • 6.45.2 Core CDx-related activities
  • 6.45.3 Partnering posture
  • 6.45.4 Differentiators
  • 6.45.5 Commercial situation
  • 6.45.6 Likely next moves
  • 6.45.7 Risks/constraints
• 6.46 Cizzle Biotech (Cizzle Biotechnology)
  • 6.46.1 Role in the CDx ecosystem
  • 6.46.2 Core CDx-related activities
  • 6.46.3 Partnering posture
  • 6.46.4 Differentiators
  • 6.46.5 Commercial situation
  • 6.46.6 Likely next moves
  • 6.46.7 Risks/constraints
• 6.47 Clearbridge Biomedics (Clearbridge BioMedics)
  • 6.47.1 Role in the CDx ecosystem
  • 6.47.2 Core CDx-related activities
  • 6.47.3 Partnering posture
  • 6.47.4 Differentiators
  • 6.47.5 Commercial situation
  • 6.47.6 Likely next moves
  • 6.47.7 Risks/constraints
• 6.48 Clinical Genomics
  • 6.48.1 Role in the CDx ecosystem
  • 6.48.2 Core CDx-related activities
  • 6.48.3 Partnering posture
  • 6.48.4 Differentiators
  • 6.48.5 Commercial situation
  • 6.48.6 Likely next moves
  • 6.48.7 Risks/constraints
• 6.49 Cytolumina Technologies Corp.
  • 6.49.1 Role in the CDx ecosystem
  • 6.49.2 Core CDx-related activities
  • 6.49.3 Partnering posture
  • 6.49.4 Differentiators
  • 6.49.5 Commercial situation
  • 6.49.6 Likely next moves
  • 6.49.7 Risks/constraints
• 6.50 Datar Cancer Genetics Limited
  • 6.50.1 Role in the CDx ecosystem
  • 6.50.2 Core CDx-related activities
  • 6.50.3 Partnering posture
  • 6.50.4 Differentiators
  • 6.50.5 Commercial situation
  • 6.50.6 Likely next moves
  • 6.50.7 Risks/constraints
• 6.51 Diagnologix LLC
  • 6.51.1 Role in the CDx ecosystem
  • 6.51.2 Core CDx-related activities
  • 6.51.3 Partnering posture
  • 6.51.4 Differentiators
  • 6.51.5 Commercial situation
  • 6.51.6 Likely next moves
• 6.52 DiaSorin S.p.A.
  • 6.52.1 Role in the CDx ecosystem
  • 6.52.2 Core CDx-related activities
  • 6.52.3 Partnering posture
  • 6.52.4 Differentiators
  • 6.52.5 Commercial situation
  • 6.52.6 Likely next moves
  • 6.52.7 Risks/constraints
• 6.53 Dxcover
  • 6.53.1 Role in the CDx ecosystem
  • 6.53.2 Core CDx-related activities
  • 6.53.3 Partnering posture
  • 6.53.4 Differentiators
  • 6.53.5 Commercial situation
  • 6.53.6 Risks/constraints
• 6.54 Element Biosciences
  • 6.54.1 Role in the CDx ecosystem
  • 6.54.2 Core CDx-related activities
  • 6.54.3 Partnering posture
  • 6.54.4 Differentiators
  • 6.54.5 Commercial situation
  • 6.54.6 Risks/constraints
• 6.55 Enzo Biochem
  • 6.55.1 Role in the CDx ecosystem
  • 6.55.2 Core CDx-related activities (as relevant today)
  • 6.55.3 Partnering posture
  • 6.55.4 Differentiators
  • 6.55.5 Commercial situation
  • 6.55.6 Risks/constraints
• 6.56 Epic Sciences
  • 6.56.1 Role in the CDx ecosystem
  • 6.56.2 Core CDx-related activities
  • 6.56.3 Partnering posture
  • 6.56.4 Differentiators
  • 6.56.5 Commercial situation
  • 6.56.6 Likely next moves
  • 6.56.7 Risks/constraints
• 6.57 Epigenomics AG
  • 6.57.1 Role in the CDx ecosystem
  • 6.57.2 Core CDx-related activities (practical read)
  • 6.57.3 Partnering posture
  • 6.57.4 Commercial situation
  • 6.57.5 Risks/constraints
• 6.58 Eurofins Scientific
  • 6.58.1 Role in the CDx ecosystem
  • 6.58.2 Core CDx-related activities
  • 6.58.3 Partnering posture
  • 6.58.4 Differentiators
  • 6.58.5 Commercial situation
  • 6.58.6 Likely next moves
• 6.59 Fabric Genomics
  • 6.59.1 Role in the CDx ecosystem
  • 6.59.2 Core CDx-related activities
  • 6.59.3 Partnering posture
  • 6.59.4 Differentiators
  • 6.59.5 Commercial situation
  • 6.59.6 Risks/constraints
• 6.60 Fluxion Biosciences (Cell Microsystems)
  • 6.60.1 Role in the CDx ecosystem
  • 6.60.2 Core CDx-related activities
  • 6.60.3 Partnering posture
  • 6.60.4 Differentiators
  • 6.60.5 Commercial situation
  • 6.60.6 Risks/constraints
• 6.61 Freenome
  • 6.61.1 Role in the CDx ecosystem
  • 6.61.2 Partnering posture
  • 6.61.3 Differentiators
  • 6.61.4 Commercial situation
  • 6.61.5 Risks/constraints
• 6.62 FUJIFILM Wako Diagnostics
  • 6.62.1 Role in the CDx ecosystem
  • 6.62.2 Core CDx-relevant activities
  • 6.62.3 Partnering posture
  • 6.62.4 Differentiators
  • 6.62.5 Commercial situation
  • 6.62.6 Risks/constraints
• 6.63 Fujirebio
  • 6.63.1 Role in the CDx ecosystem
  • 6.63.2 Core CDx-relevant activities
  • 6.63.3 Partnering posture
  • 6.63.4 Differentiators
  • 6.63.5 Commercial situation
  • 6.63.6 Risks/constraints
• 6.64 Fyr Diagnostics (FYR Bio)
  • 6.64.1 Role in the CDx ecosystem
  • 6.64.2 Core CDx-relevant activities
  • 6.64.3 Partnering posture
  • 6.64.4 Differentiators
  • 6.64.5 Commercial situation
  • 6.64.6 Risks/constraints
• 6.65 GeneDx Holdings
  • 6.65.1 Role in the CDx ecosystem
  • 6.65.2 Partnering posture
  • 6.65.3 Differentiators
  • 6.65.4 Commercial situation
  • 6.65.5 Risks/constraints
• 6.66 GeneFirst Ltd.
  • 6.66.1 Role in the CDx ecosystem
  • 6.66.2 Core CDx-related activities
  • 6.66.3 Partnering posture
  • 6.66.4 Differentiators
  • 6.66.5 Commercial situation
  • 6.66.6 Risks/constraints
• 6.67 Genetron Holdings
  • 6.67.1 Role in the CDx ecosystem
  • 6.67.2 Core CDx-related activities
  • 6.67.3 Partnering posture
  • 6.67.4 Differentiators
  • 6.67.5 Commercial situation
  • 6.67.6 Risks/constraints
• 6.68 GenomOncology
  • 6.68.1 Role in the CDx ecosystem
  • 6.68.2 Core CDx-related activities
  • 6.68.3 Partnering posture
  • 6.68.4 Differentiators
  • 6.68.5 Commercial situation
  • 6.68.6 Risks/constraints
• 6.69 GILUPI Nanomedizin
  • 6.69.1 Role in the CDx ecosystem
  • 6.69.2 Core CDx-related activities
  • 6.69.3 Partnering posture
  • 6.69.4 Differentiators
  • 6.69.5 Commercial situation
  • 6.69.6 Risks/constraints
• 6.70 Guardant Health
  • 6.70.1 Role in the CDx ecosystem
  • 6.70.2 Core CDx-related activities
  • 6.70.3 Partnering posture
  • 6.70.4 Differentiators
  • 6.70.5 Commercial situation
  • 6.70.6 Risks/constraints
• 6.71 HansaBiomed
  • 6.71.1 Role in the CDx ecosystem
  • 6.71.2 Core CDx-relevant activities
  • 6.71.3 Partnering posture
  • 6.71.4 Differentiators
  • 6.71.5 Commercial situation
  • 6.71.6 Risks/constraints
• 6.72 HTG Molecular Diagnostics
  • 6.72.1 Role in the CDx ecosystem
  • 6.72.2 Core CDx-relevant activities
  • 6.72.3 Commercial situation (important context)
  • 6.72.4 Partnering posture
  • 6.72.5 Differentiators
  • 6.72.6 Risks/constraints
• 6.73 iCellate
  • 6.73.1 Role in the CDx ecosystem
  • 6.73.2 Core CDx-relevant activities
  • 6.73.3 Partnering posture
  • 6.73.4 Differentiators
  • 6.73.5 Commercial situation
  • 6.73.6 Risks/constraints
• 6.74 ICON plc
  • 6.74.1 Role in the CDx ecosystem
  • 6.74.2 Core CDx-relevant activities
  • 6.74.3 Partnering posture
  • 6.74.4 Differentiators
  • 6.74.5 Commercial situation
  • 6.74.6 Risks/constraints
• 6.75 Illumina
  • 6.75.1 Role in the CDx ecosystem
  • 6.75.2 Core CDx-relevant activities
  • 6.75.3 Partnering posture
  • 6.75.4 Differentiators
  • 6.75.5 Risks/constraints
• 6.76 Incell Dx
  • 6.76.1 Role in the CDx ecosystem
  • 6.76.2 Core CDx-relevant activities
  • 6.76.3 Partnering posture
  • 6.76.4 Differentiators
  • 6.76.5 Commercial situation
• 6.77 Inivata
  • 6.77.1 Role in the CDx ecosystem
  • 6.77.2 Core CDx-relevant activities
  • 6.77.3 Partnering posture
  • 6.77.4 Differentiators
  • 6.77.5 Commercial situation
• 6.78 INOVIQ
  • 6.78.1 Role in the CDx ecosystem
  • 6.78.2 Core CDx-relevant activities
  • 6.78.3 Partnering posture
  • 6.78.4 Differentiators
  • 6.78.5 Commercial situation
• 6.79 InvivoGen
  • 6.79.1 Role in the CDx ecosystem
  • 6.79.2 Core CDx-relevant activities
  • 6.79.3 Partnering posture
  • 6.79.4 Differentiators
  • 6.79.5 Commercial situation
• 6.80 Invivoscribe
  • 6.80.1 Role in the CDx ecosystem
  • 6.80.2 Core CDx-related activities
  • 6.80.3 Partnering posture
  • 6.80.4 Differentiators
  • 6.80.5 Commercial situation
• 6.81 J&J Innovative Medicine
  • 6.81.1 Role in the CDx ecosystem
  • 6.81.2 Core CDx-related activities
  • 6.81.3 Partnering posture
  • 6.81.4 Differentiators
  • 6.81.5 Commercial situation
  • 6.81.6 Risks/constraints
• 6.82 Lucence Health
  • 6.82.1 Role in the CDx ecosystem
  • 6.82.2 Core CDx-related activities
  • 6.82.3 Partnering posture
  • 6.82.4 Differentiators
  • 6.82.5 Commercial situation
  • 6.82.6 Risks/constraints
• 6.83 LungLife AI Inc
  • 6.83.1 Role in the CDx ecosystem
  • 6.83.2 Core CDx-related activities
  • 6.83.3 Partnering posture
  • 6.83.4 Differentiators
  • 6.83.5 Commercial situation
  • 6.83.6 Risks/constraints
• 6.84 MDxHealth
  • 6.84.1 Role in the CDx ecosystem
  • 6.84.2 Core CDx-related activities
  • 6.84.3 Partnering posture
  • 6.84.4 Differentiators
  • 6.84.5 Commercial situation
  • 6.84.6 Risks/constraints
• 6.85 Menarini Silicon Biosystems
  • 6.85.1 Role in the CDx ecosystem
  • 6.85.2 Core CDx-relevant activities
  • 6.85.3 Partnering posture
  • 6.85.4 Differentiators
  • 6.85.5 Commercial situation
  • 6.85.6 Risks/constraints
• 6.86 Mesa Laboratories, Inc.
  • 6.86.1 Role in the CDx ecosystem
  • 6.86.2 Core CDx-relevant activities
  • 6.86.3 Partnering posture
  • 6.86.4 Differentiators
  • 6.86.5 Commercial situation
  • 6.86.6 Risks/constraints
• 6.87 Millipore Sigma (MilliporeSigma / Merck KGaA Life Science)
  • 6.87.1 Role in the CDx ecosystem
  • 6.87.2 Core CDx-relevant activities
  • 6.87.3 Partnering posture
  • 6.87.4 Differentiators
  • 6.87.5 Commercial situation
  • 6.87.6 Risks/constraints
• 6.88 Miltenyi Biotec
  • 6.88.1 Role in the CDx ecosystem
  • 6.88.2 Core CDx-relevant activities
  • 6.88.3 Partnering posture
  • 6.88.4 Differentiators
  • 6.88.5 Commercial situation
  • 6.88.6 Risks/constraints
• 6.89 miR Scientific
  • 6.89.1 Role in the CDx ecosystem
  • 6.89.2 Core CDx-relevant activities
  • 6.89.3 Partnering posture
  • 6.89.4 Differentiators
  • 6.89.5 Commercial situation
  • 6.89.6 Risks/constraints
• 6.90 Myriad Genetics (Myriad Oncology)
  • 6.90.1 Role in the CDx ecosystem
  • 6.90.2 Core CDx-related activities
  • 6.90.3 Biopharma partnering posture
  • 6.90.4 Differentiators
  • 6.90.5 Commercial situation
• 6.91 NanoString (Bruker)
  • 6.91.1 Role in the CDx ecosystem
  • 6.91.2 Core CDx-relevant activities (practical view)
  • 6.91.3 Partnering posture
  • 6.91.4 Differentiators
  • 6.91.5 Commercial situation
• 6.92 NantHealth (GPS Cancer / NantOmics ecosystem)
  • 6.92.1 Role in the CDx ecosystem
  • 6.92.2 Core CDx-relevant activities
  • 6.92.3 Partnering posture
  • 6.92.4 Differentiators
  • 6.92.5 Commercial situation
• 6.93 Natera (Signatera MRD and ctDNA monitoring)
  • 6.93.1 Role in the CDx ecosystem
  • 6.93.2 Core CDx-relevant activities
  • 6.93.3 Differentiators
  • 6.93.4 Commercial situation
• 6.94 NeoGenomics
  • 6.94.1 Role in the CDx ecosystem
  • 6.94.2 Core CDx-relevant activities
  • 6.94.3 Partnering posture
  • 6.94.4 Differentiators
  • 6.94.5 Commercial situation
• 6.95 NGeneBio
  • 6.95.1 Role in the CDx ecosystem
  • 6.95.2 Core CDx-related activities
  • 6.95.3 Partnering posture
  • 6.95.4 Differentiators
  • 6.95.5 Commercial situation
• 6.96 Novogene
  • 6.96.1 Role in the CDx ecosystem
  • 6.96.2 Core CDx-related activities
  • 6.96.3 Partnering posture
  • 6.96.4 Differentiators
  • 6.96.5 Commercial situation
• 6.97 OncoDNA
  • 6.97.1 Role in the CDx ecosystem
  • 6.97.2 Core CDx-related activities
  • 6.97.3 Partnering posture
  • 6.97.4 Differentiators
  • 6.97.5 Commercial situation
• 6.98 OncoHost
  • 6.98.1 Role in the CDx ecosystem
  • 6.98.2 Core CDx-related activities
  • 6.98.3 Partnering posture
  • 6.98.4 Differentiators
  • 6.98.5 Commercial situation
• 6.99 Oxford Nanopore Technologies
  • 6.99.1 Role in the CDx ecosystem
  • 6.99.2 Core CDx-related activities
  • 6.99.3 Partnering posture
  • 6.99.4 Differentiators
  • 6.99.5 Commercial situation
• 6.100 PamGene
  • 6.100.1 Role in the CDx ecosystem
  • 6.100.2 Core CDx-related activities
  • 6.100.3 Partnering posture
  • 6.100.4 Differentiators
  • 6.100.5 Commercial situation
• 6.101 Panagene (HLB Panagene)
  • 6.101.1 Role in the CDx ecosystem
  • 6.101.2 Core CDx-related activities
  • 6.101.3 Partnering posture
  • 6.101.4 Differentiators
  • 6.101.5 Commercial situation
• 6.102 Personalis
  • 6.102.1 Role in the CDx ecosystem
  • 6.102.2 Core CDx-related activities
  • 6.102.3 Partnering posture
  • 6.102.4 Differentiators
  • 6.102.5 Commercial situation
• 6.103 Perthera
  • 6.103.1 Role in the CDx ecosystem
  • 6.103.2 Core CDx-relevant activities
  • 6.103.3 Strategy & partnering posture
  • 6.103.4 Differentiators
  • 6.103.5 Commercial situation
• 6.104 PGDx (Labcorp)
  • 6.104.1 Role in the CDx ecosystem
  • 6.104.2 Core CDx-related activities
  • 6.104.3 Strategy & partnering posture
  • 6.104.4 Differentiators
  • 6.104.5 Commercial situation
• 6.105 Precipio
  • 6.105.1 Role in the CDx ecosystem
  • 6.105.2 Core CDx-related activities
  • 6.105.3 Strategy & partnering posture
  • 6.105.4 Differentiators
  • 6.105.5 Commercial situation
• 6.106 Predicine
  • 6.106.1 Role in the CDx ecosystem
  • 6.106.2 Core CDx-related activities
  • 6.106.3 Strategy & partnering posture
  • 6.106.4 Differentiators
  • 6.106.5 Commercial situation
• 6.107 Predictive Oncology
  • 6.107.1 Role in the CDx ecosystem
  • 6.107.2 Core CDx-relevant activities
  • 6.107.3 Strategy & partnering posture
  • 6.107.4 Differentiators
  • 6.107.5 Commercial situation
• 6.108 Promega
  • 6.108.1 Role in the CDx ecosystem
  • 6.108.2 Core CDx-related activities
  • 6.108.3 Strategy & partnering posture
  • 6.108.4 Differentiators
  • 6.108.5 Commercial situation
• 6.109 QIAGEN
  • 6.109.1 Role in the CDx ecosystem
  • 6.109.2 Core CDx-related activities
  • 6.109.3 Strategy & partnering posture
  • 6.109.4 Differentiators
  • 6.109.5 Commercial situation
• 6.110 QuidelOrtho
  • 6.110.1 Role in the CDx ecosystem
  • 6.110.2 Core CDx-relevant activities
  • 6.110.3 Strategy & partnering posture
  • 6.110.4 Differentiators
  • 6.110.5 Commercial situation
• 6.111 Rarecells SAS
  • 6.111.1 Role in the CDx ecosystem
  • 6.111.2 Core CDx-relevant activities
  • 6.111.3 Strategy & partnering posture
  • 6.111.4 Differentiators
  • 6.111.5 Commercial situation
• 6.112 RareCyte
  • 6.112.1 Role in the CDx ecosystem
  • 6.112.2 Core CDx-relevant activities
  • 6.112.3 Strategy & partnering posture
  • 6.112.4 Differentiators
  • 6.112.5 Commercial situation
• 6.113 Revvity
  • 6.113.1 Role in the CDx ecosystem
  • 6.113.2 Core CDx-relevant activities
  • 6.113.3 Strategy & partnering posture
  • 6.113.4 Differentiators
  • 6.113.5 Commercial situation
• 6.114 Roche Diagnostics
  • 6.114.1 Role in the CDx ecosystem
  • 6.114.2 Core CDx-relevant activities
  • 6.114.3 Strategy & partnering posture
  • 6.114.4 Differentiators
  • 6.114.5 Commercial situation
• 6.115 ScreenCell
  • 6.115.1 Role in the CDx ecosystem
  • 6.115.2 Core CDx-relevant activities
  • 6.115.3 Strategy & partnering posture
  • 6.115.4 Differentiators
  • 6.115.5 Commercial situation
• 6.116 Sherlock Biosciences
  • 6.116.1 Role in the CDx ecosystem
  • 6.116.2 Core CDx-relevant activities
  • 6.116.3 Strategy & partnering posture
  • 6.116.4 Differentiators
  • 6.116.5 Commercial situation
• 6.117 simfo GmbH
  • 6.117.1 Role in the CDx ecosystem
  • 6.117.2 Core CDx-relevant activities
  • 6.117.3 Strategy & partnering posture
  • 6.117.4 Differentiators
  • 6.117.5 Commercial situation
• 6.118 Singlera Genomics Inc.
  • 6.118.1 Role in the CDx ecosystem
  • 6.118.2 Core CDx-relevant activities
  • 6.118.3 Strategy & partnering posture
  • 6.118.4 Differentiators
  • 6.118.5 Commercial situation
• 6.119 Singular Genomics
  • 6.119.1 Role in the CDx ecosystem
  • 6.119.2 Core CDx-relevant activities
  • 6.119.3 Strategy & partnering posture
  • 6.119.4 Differentiators
  • 6.119.5 Commercial situation
• 6.120 Singulomics (SingulOmics)
  • 6.120.1 Role in the CDx ecosystem
  • 6.120.2 Core CDx-relevant activities
  • 6.120.3 Strategy & partnering posture
  • 6.120.4 Differentiators
  • 6.120.5 Commercial situation
• 6.121 SkylineDx
  • 6.121.1 Role in the CDx ecosystem
  • 6.121.2 Core CDx-relevant activities
  • 6.121.3 Strategy & partnering posture
  • 6.121.4 Differentiators
  • 6.121.5 Commercial situation
• 6.122 Standard BioTools (formerly Fluidigm)
  • 6.122.1 Role in the CDx ecosystem
  • 6.122.2 Core CDx-relevant activities
  • 6.122.3 Strategy & partnering posture
  • 6.122.4 Differentiators
  • 6.122.5 Commercial situation
• 6.123 Stilla Technologies
  • 6.123.1 Role in the CDx ecosystem
  • 6.123.2 Core CDx-relevant activities
  • 6.123.3 Strategy & partnering posture
  • 6.123.4 Differentiators
  • 6.123.5 Commercial situation
• 6.124 Sysmex Inostics
  • 6.124.1 Role in the CDx ecosystem
  • 6.124.2 Core CDx-relevant activities
  • 6.124.3 Strategy & partnering posture
  • 6.124.4 Differentiators
  • 6.124.5 Commercial situation
• 6.125 Tempus Labs (Tempus AI)
  • 6.125.1 Role in the CDx ecosystem
  • 6.125.2 Core CDx-related activities
  • 6.125.3 Strategy & partnering posture
  • 6.125.4 Differentiators
  • 6.125.5 Commercial situation
• 6.126 Thermo Fisher Scientific
  • 6.126.1 Role in the CDx ecosystem
  • 6.126.2 Core CDx-related activities
  • 6.126.3 Strategy & partnering posture
  • 6.126.4 Differentiators
  • 6.126.5 Commercial situation
• 6.127 Todos Medical
  • 6.127.1 Role in the CDx ecosystem
  • 6.127.2 Core CDx-relevant activities
  • 6.127.3 Strategy & partnering posture
  • 6.127.4 Differentiators
  • 6.127.5 Commercial situation
• 6.128 Ultima Genomics
  • 6.128.1 Role in the CDx ecosystem
  • 6.128.2 Core CDx-relevant activities
  • 6.128.3 Strategy & partnering posture
  • 6.128.4 Differentiators
  • 6.128.5 Commercial situation
• 6.129 Veracyte
  • 6.129.1 Role in the CDx ecosystem
  • 6.129.2 Core CDx-relevant activities
  • 6.129.3 Strategy & partnering posture
  • 6.129.4 Differentiators
  • 6.129.5 Commercial situation
• 6.130 Vir Biotechnology
  • 6.130.1 Role in the CDx ecosystem
  • 6.130.2 Core oncology activities that drive CDx needs
  • 6.130.3 Partnering posture
  • 6.130.4 Commercial situation (as a CDx "influencer")
• 6.131 VolitionRX
  • 6.131.1 Role in the CDx ecosystem
  • 6.131.2 Core activities and current positioning
  • 6.131.3 Strategy & partnering posture
  • 6.131.4 Commercial situation
• 6.132 Vortex Biosciences
  • 6.132.1 Role in the CDx ecosystem
  • 6.132.2 Core CDx-relevant activities
  • 6.132.3 Strategy & partnering posture
  • 6.132.4 Commercial situation

7 The Global Market for Companion Diagnostics

• 7.1 Global Market Overview by Country
  • 7.1.1 Table - Global Market by Country
  • 7.1.2 Chart - Global Market by Country
• 7.2 Global Market by Application - Overview
  • 7.2.1 Table - Global Market by Application
  • 7.2.2 Chart - Global Market by Application - Base/Final Year Comparison
  • 7.2.3 Chart - Global Market by Application - Base Year
  • 7.2.4 Chart - Global Market by Application - Final Year
  • 7.2.5 Chart - Global Market by Application - Share by Year
  • 7.2.6 Chart - Global Market by Application - Segment Growth Rates
• 7.3 Global Market by Technology - Overview
  • 7.3.1 Table - Global Market by Technology
  • 7.3.2 Chart - Global Market Technology - Base/Final Year Comparison
  • 7.3.3 Chart - Global Market Technology - Base Year
  • 7.3.4 Chart - Global Market Technology - Final Year
  • 7.3.5 Chart - Global Market Technology - Share by Year
  • 7.3.6 Chart - Global Market Technology - Segment Growth Rates
• 7.4 Global Market by User - Overview
  • 7.4.1 Table - Global Market by User
  • 7.4.2 Chart - Global Market by User - Base/Final Year Comparison
  • 7.4.3 Chart - Global Market by User - Base Year
  • 7.4.4 Chart - Global Market by User - Final Year
  • 7.4.5 Chart - Global Market by User - Share by Year
  • 7.4.6 Chart - Global Market by User - Segment Growth Rates
• 7.5 Global Market by Product - Overview
  • 7.5.1 Table - Global Market by Product
  • 7.5.2 Chart - Global Market by Product - Base/Final Year Comparison
  • 7.5.3 Chart - Global Market by Product - Base Year
  • 7.5.4 Chart - Global Market by Product - Final Year
  • 7.5.5 Chart - Global Market by Product - Share by Year
  • 7.5.6 Chart - Global Market by Product - Segment Growth Rates

8 Global Companion Diagnostic Markets - By Application

• 8.1 Oncology Breast
  • 8.1.1 Table Oncology Breast - by Country
  • 8.1.2 Chart - Oncology Breast Growth
• 8.2 Oncology Lung
  • 8.2.1 Table Oncology Lung - by Country
  • 8.2.2 Chart - Oncology Lung Growth
• 8.3 Oncology Colorectal
  • 8.3.1 Table Oncology Colorectal - by Country
  • 8.3.2 Chart - Oncology Colorectal Growth
• 8.4 Oncology Other
  • 8.4.1 Table Oncology Other - by Country
  • 8.4.2 Chart - Oncology Other Growth
• 8.5 Neurology
  • 8.5.1 Table Neurology - by Country
  • 8.5.2 Chart - Neurology Growth
• 8.6 Cardiology
  • 8.6.1 Table Cardiology - by Country
  • 8.6.2 Chart - Cardiology Growth
• 8.7 Other Application
  • 8.7.1 Table Other Application - by Country
  • 8.7.2 Chart - Other Application Growth

9 Global Companion Diagnostic Markets - Technology

• 9.1 Global Market Next Generation Sequencing
  • 9.1.1 Table Next Generation Sequencing - by Country
  • 9.1.2 Chart - Next Generation Sequencing Growth
• 9.2 Global Market PCR
  • 9.2.1 Table PCR - by Country
  • 9.2.2 Chart - PCR Growth
• 9.3 Global Market IHC/ISH
  • 9.3.1 Table IHC/ISH - by Country
  • 9.3.2 Chart - IHC/ISH Growth
• 9.4 Global Market Liquid Biopsy
  • 9.4.1 Table Liquid Biopsy - by Country
  • 9.4.2 Chart - Liquid Biopsy Growth
• 9.5 Global Market Other Technology
  • 9.5.1 Table Other Technology - by Country
  • 9.5.2 Chart - Other Technology Growth

10 Global Companion Diagnostic Markets - User

• 10.1 Global Market Clinical Laboratories
  • 10.1.1 Table Clinical Laboratories - by Country
  • 10.1.2 Chart - Clinical Laboratories Growth
• 10.2 Global Market Pharmaceutical
  • 10.2.1 Table Pharmaceutical - by Country
  • 10.2.2 Chart - Pharmaceutical Growth
• 10.3 Global Market Contract Research Org
  • 10.3.1 Table Contract Research Org - by Country
  • 10.3.2 Chart - Contract Research Org Growth
• 10.4 Global Market In Vitro Dx Company
  • 10.4.1 Table In Vitro Dx Company - by Country
  • 10.4.2 Chart - In Vitro Dx Company Growth
• 10.5 Global Market Other User
  • 10.5.1 Table Other User - by Country
  • 10.5.2 Chart - Other User Growth

11 Global Companion Diagnostic Markets - Product

• 11.1 Global Market Instruments
  • 11.1.1 Table Instruments - by Country
  • 11.1.2 Chart - Instruments Growth
• 11.2 Global Market Kits and Reagents
  • 11.2.1 Table Kits and Reagents - by Country
  • 11.2.2 Chart - Kits and Reagents Growth
• 11.3 Global Market Software/Services
  • 11.3.1 Table Software/Services - by Country
  • 11.3.2 Chart - Software/Services Growth
• 11.4 Global Market Other Product
  • 11.4.1 Table Other Product - by Country
  • 11.4.2 Chart - Other Product Growth

12 Appendices

• 12.1 United States Medicare System: Clinical Laboratory Fees Schedule
• 12.2 The Most Used IVD Assays
• 12.3 The Highest Grossing Assays

Table of Tables

• Table 1 FDA Approved Companion Dx
• Table 2 Market Players by Type
• Table 3 The Base Pairs
• Table 4 Factors Driving Growth
• Table 5 Factors Limiting Growth
• Table 6 Seven Key Diagnostic Laboratory Technology Trends
• Table 7 Global Companion Diagnostic Market by Region
• Table 8 Global Market by Application
• Table 9 Global Market by Technology
• Table 10 Global Market by User
• Table 11 Global Market by Product
• Table 12 Oncology Breast by Country
• Table 13 Oncology Lung by Country
• Table 14 Oncology Colorectal by Country
• Table 15 Oncology Other by Country
• Table 16 Neurology by Country
• Table 17 Cardiology by Country
• Table 18 Other Application by Country
• Table 19 Next Generation Sequencing by Country
• Table 20 PCR by Country
• Table 21 IHC/ISH by Country
• Table 22 Liquid Biopsy by Country
• Table 23 Other Technology by Country
• Table 24 Clinical Laboratories by Country
• Table 25 Pharmaceutical by Country
• Table 26 Contract Research Org by Country
• Table 27 In Vitro Dx Company by Country
• Table 28 Other User by Country
• Table 29 Instruments by Country
• Table 30 Kits and Reagents by Country
• Table 31 Software/Services by Country
• Table 32 Other Product by Country
• Table 33 Clinical Laboratory Fee Schedule
• Table 34 The Most Common Assays
• Table 35 Largest Revenue Assays

Table of Figures

• Figure 1 Global Healthcare Spending
• Figure 2 The Road to Diagnostics
• Figure 3 DNA Strands and Chromosomes
• Figure 4 Karyogram of Human Chromosomes
• Figure 5 Size of Various Genomes
• Figure 6 Germline vs Somatic Mutations
• Figure 7 Comparing Genomic Diagnostic and Traditional Testing
• Figure 8 The Changing Age of The World's Population
• Figure 9 Health Care Consumption by Age
• Figure 10 Cancer Incidence by Age
• Figure 11 Centralized vs. Decentralized Laboratory Service
• Figure 12 A Highly Multiplexed Syndromic Testing Unit
• Figure 13 The Real Cost to Sequence the Human Genome
• Figure 14 The Codevelopment Process
• Figure 15 Comparing MDx Diagnostic and Traditional Testing
• Figure 16 Base Year Country Market Share Chart
• Figure 17 CDx Market by Application - Base vs. Final Year
• Figure 18 CDx Market by Application Base Year
• Figure 19 CDx Market by Application Final Year
• Figure 20 Application Type Share by Year
• Figure 21 Application Type Segment Growth Rates
• Figure 22 Technology - Base vs. Final Year
• Figure 23 Technology Market Base Year
• Figure 24 Technology Market Final Year
• Figure 25 Technology Share by Year
• Figure 25 Technology Type Segment Growth Rates
• Figure 26 CDx Market by User - Base vs. Final Year
• Figure 27 CDx Market by User Base Year
• Figure 28 CDx Market by User Final Year
• Figure 29 User Type Share by Year
• Figure 30 User Type Segment Growth Rates
• Figure 31 CDx Market by Product - Base vs. Final Year
• Figure 32 CDx Market by Product Base Year
• Figure 33 CDx Market by Product Final Year
• Figure 34 Product Type Share by Year
• Figure 35 Product Type Segment Growth Rates
• Figure 36 Oncology Breast Growth
• Figure 37 Oncology Lung Growth
• Figure 38 Oncology Colorectal Growth
• Figure 39 Oncology Other Growth
• Figure 40 Neurology Growth
• Figure 41 Cardiology Growth
• Figure 42 Other Application Growth
• Figure 43 Next Generation Sequencing Growth
• Figure 44 PCR Growth
• Figure 45 IHC/ISH Growth
• Figure 46 Liquid Biopsy Growth
• Figure 47 Other Technology Growth
• Figure 48 Clinical Laboratories Growth
• Figure 49 Pharmaceutical Growth
• Figure 50 Contract Research Org Growth
• Figure 51 In Vitro Dx Company Growth
• Figure 52 Other User Growth
• Figure 53 Instruments Growth
• Figure 54 Kits and Reagents Growth
• Figure 55 Software/Services Growth
• Figure 56 Other Product Growth